The enhancement of FGL1 levels was regulated by IL-6 [20, 21] and it participates in the development of non-alcoholic fatty liver disease, hepatocellular carcinomas, and hepatocyte mitogenic activity [22–26]. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.